References
- Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551–60.
- De Vooght KMK, Oostendorp M, Van Solinge WW. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing. Curr Opin Hematol 2016;23:557–62.
- Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545–54.
- van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 2016;127:681–96.
- Mehta K, Shahid U. CD38: a cell-surface protein with multiple functions. FASEB J 1996;10:1408–17.
- AABB Association Bulletin #16-02 Mitigating the Anti-CD38 Interference with Serologic Testing. 2016. Available from
https://www.aabb.org/programs/publications/bulletins/Documents/ab16-02.pdf . - Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion 2016;12: 2964–72.
- Cooling L, Downs T. Immunohematology. In: Hutchinson R, McPherson R, Schexneider K, eds. Henry’s clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia, PA: Elsevier Saunders 2011:674–730.
- Schmidt AE, Kirkley S, Patel N, et al. An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab. Transfusion 2015;55:2292–3.
- Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. Technical manual. 18th ed. Bethesda, MD: AABB, 2014.